158 related articles for article (PubMed ID: 8867429)
21. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: dependence on field strength and plasma concentration--preliminary clinical experience with dynamic T1-weighted MR imaging.
Reimer P; Müller M; Marx C; Wiedermann D; Muller R; Rummeny EJ; Ebert W; Shamsi K; Peters PE
Radiology; 1998 Dec; 209(3):831-6. PubMed ID: 9844683
[TBL] [Abstract][Full Text] [Related]
22. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
Giovagnoni A; Paci E
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
[TBL] [Abstract][Full Text] [Related]
23. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA.
Stern W; Schick F; Kopp AF; Reimer P; Shamsi K; Claussen CD; Laniado M
Acta Radiol; 2000 May; 41(3):255-62. PubMed ID: 10866081
[TBL] [Abstract][Full Text] [Related]
24. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: a potential new sign for characterization of liver lesions.
Mergo PJ; Helmberger T; Nicolas AI; Ros PR
AJR Am J Roentgenol; 1996 Feb; 166(2):379-84. PubMed ID: 8553952
[TBL] [Abstract][Full Text] [Related]
25. [Use of SPIO-enhanced T1- and T2-weighted images for the differentiation of liver lesions: an ROC analysis].
Stroszczynski C; Gaffke G; Gretschel S; Rambow A; Jost D; Schlecht I; Schneider U; Schicke B; Hohenberger P; Gebauer B; Felix R
Rofo; 2003 Oct; 175(10):1368-75. PubMed ID: 14556106
[TBL] [Abstract][Full Text] [Related]
26. Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.
Tang Y; Yamashita Y; Arakawa A; Namimoto T; Mitsuzaki K; Abe Y; Katahira K; Takahashi M
AJR Am J Roentgenol; 1999 Jun; 172(6):1547-54. PubMed ID: 10350287
[TBL] [Abstract][Full Text] [Related]
27. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient.
Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R
Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049
[No Abstract] [Full Text] [Related]
28. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
De Gaspari A; De Cobelli F; Del Maschio A
Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of radiation-induced liver injury with MR imaging: comparison of hepatocellular and reticuloendothelial contrast agents.
Clément O; Mühler A; Vexler VS; Rosenau W; Berthezène Y; Kuwatsuru R; Brasch RC
Radiology; 1992 Oct; 185(1):163-8. PubMed ID: 1523301
[TBL] [Abstract][Full Text] [Related]
30. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging.
Saini S; Sharma R; Baron RL; Turner DA; Ros PR; Hahn PF; Small WC; Delange EE; Stillman AE; Edelman RR; Runge VM; Outwater EK
Clin Radiol; 2000 Sep; 55(9):690-5. PubMed ID: 10988047
[TBL] [Abstract][Full Text] [Related]
31. Optimal MR protocol for hepatic hemangiomas. Comparison of conventional spin-echo sequences with T2-weighted turbo spin-echo and serial gradient-echo (FLASH) sequences with gadolinium enhancement.
Kim TK; Choi BI; Han JK; Jang HJ; Han MC
Acta Radiol; 1997 Jul; 38(4 Pt 1):565-71. PubMed ID: 9240679
[TBL] [Abstract][Full Text] [Related]
32. Detection of focal liver lesions with superparamagnetic iron oxide: value of STIR and SE imaging.
Halavaara JT; Lamminen AE; Bondestam S; Standertskjöld-Nordenstam CG; Hamberg LM
J Comput Assist Tomogr; 1994; 18(6):897-904. PubMed ID: 7962796
[TBL] [Abstract][Full Text] [Related]
33. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
[TBL] [Abstract][Full Text] [Related]
34. Combined use of MR contrast agents for evaluating liver disease.
Ward J; Robinson PJ
Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):767-802, vi. PubMed ID: 11694437
[TBL] [Abstract][Full Text] [Related]
35. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging.
Lee JM; Kim CS; Youk JH; Lee MS
Korean J Radiol; 2003; 4(1):9-18. PubMed ID: 12679629
[TBL] [Abstract][Full Text] [Related]
36. [Differential diagnosis of intra- and perilienal tumors by use of a RES-specific MRI contrast agent].
Gaffke G; Stroszczynski C; Gnauck M; Jost D; Chmelik P; Ludwig WD; Gretschel S; Felix R
Rontgenpraxis; 2004; 55(5):192-9. PubMed ID: 15700656
[TBL] [Abstract][Full Text] [Related]
37. Quantitative assessment of iron-oxide-enhanced magnetic resonance imaging of the liver: Vessel isointensity is a potential characteristic of liver hemangiomas on late T1-weighted images.
Schmitz SA; Nikolova A; O'Regan D; Albrecht T; Hohmann J; Wolf KJ
Acta Radiol; 2006 Sep; 47(7):634-42. PubMed ID: 16950695
[TBL] [Abstract][Full Text] [Related]
38. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
Reimer P; Schneider G; Schima W
Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
[TBL] [Abstract][Full Text] [Related]
39. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
[TBL] [Abstract][Full Text] [Related]
40. Sequential use of ferumoxide particles and gadolinium chelate for the evaluation of focal liver lesions on MRI.
Semelka RC; Lee JK; Worawattanakul S; Noone TC; Patt RH; Ascher SM
J Magn Reson Imaging; 1998; 8(3):670-4. PubMed ID: 9626884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
